Lrg1 Antagonist Therapy for Vasculoproliferative Conditions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sight-threatening conditions like diabetic retinopathy and tumour growth, which involve uncontrolled vascular proliferation, rely heavily on VEGF targeting but face long-term efficacy concerns and off-target effects, necessitating alternative therapeutic targets with fewer side effects.
Innovation Solution
Identification of Leucine-rich alpha-2-glycoprotein 1 (Lrg1) as a drugable target for modulating pathogenic vascular remodelling, using antagonists such as antibodies and peptides that bind to Lrg1 to block its interaction with the TGFβ signalling pathway, thereby diverting activity away from vasculopathogenic cascades.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-VEGF therapy is used to treat retinal vascular conditions, then short-term clinical outcome is improved, but long-term efficacy is compromised due to VEGF's neuroprotective activities and housekeeping roles
Solution Approach 1:
The patent introduces Lrg1 as an intermediary molecule in the TGFβ signalling pathway that mediates pathogenic vascular remodelling. By targeting Lrg1 instead of VEGF directly, the therapy blocks vascular pathology through TGFβ pathway modulation while leaving VEGF's essential neuroprotective and housekeeping functions intact, thus resolving the contradiction between short-term efficacy and long-term safety
Solution Approach 2:
The patent extracts the specific pathogenic component (Lrg1) from the broader VEGF signalling system. Lrg1 is identified as a downstream effector that specifically drives pathological vascular changes, separating this harmful function from VEGF's beneficial roles. This extraction allows selective inhibition of pathology while preserving essential physiological functions
2Object-affected harmful factors
If VEGF pathway targeting is used to inhibit angiogenesis, then neoangiogenesis is suppressed, but other vascular changes such as telangiectasia are not addressed and off-target effects occur
Solution Approach 1:
The patent demonstrates that Lrg1 antagonism provides universal therapy for multiple vascular pathologies. By blocking Lrg1 in the TGFβ pathway, the treatment simultaneously addresses neoangiogenesis, telangiectasia, and other vascular remodelling conditions that were not effectively covered by VEGF targeting alone, thus achieving multi-functional therapeutic coverage
Solution Approach 2:
Lrg1 serves as a common intermediary downstream of multiple pro-angiogenic signals including VEGF and other growth factors. By blocking this convergent pathway at the Lrg1 level, the therapy effectively suppresses diverse vascular pathologies through a single target, providing versatile coverage without needing to address each pathway separately
3Productivity
If existing VEGF-based therapies are used, then vascular proliferation is inhibited, but interference with normal vascular processes occurs due to VEGF's multiple roles
Solution Approach 1:
The patent extracts and targets specifically the pathogenic Lrg1 component that drives abnormal vascular proliferation, separating it from VEGF's normal physiological functions. This selective extraction allows inhibition of pathological growth while sparing normal vascular processes that depend on VEGF's housekeeping and neuroprotective roles
Solution Approach 2:
By targeting Lrg1 as an intermediary downstream effector rather than VEGF itself, the therapy achieves vascular proliferation inhibition through TGFβ pathway modulation while indirectly preserving VEGF's essential functions. This intermediary targeting approach reduces off-target effects on normal vascular processes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of Lrg1 antagonists effectively reduces vascular proliferation and angiogenesis, offering a potentially superior approach to VEGF targeting by minimizing interference with normal vascular processes and providing a systemic therapeutic route.
Implementation Method 1
an antagonist of Lrg1 for use in the treatment or prevention of pathogenic vascularisation, wherein said antagonist is an antibody that binds to Lrg1
Data Source
Figure 1
Figure 2A~2B
Figure 3A~3D
AI summary
This invention relates to the field of molecular physiology. Specifically, this invention relates to the prevention and/or treatment of vasculoproliferative conditions, especially those of the eye and in the treatment of tumours that exhibit vascular proliferation. Levels of leucine-rich alpha-2-glycoprotein (Lrg1) have been demonstrated to be increased in patients suffering from such conditions and animal models of such conditions. Antagonists of Lrg1 can be used to prevent and/or treat vasculoproliferative conditions.